Legal Statement

Important Safety Information, including boxed WARNING

Lower respiratory tract infections, including pneumonia, have been reported following the inhaled administration of corticosteroids

  • In 2 placebo-controlled SYMBICORT COPD clinical studies, pneumonia did not occur with greater incidence in the SYMBICORT 160/4.5 group, compared with placebo, while the incidence of lung infections other than pneumonia (eg, bronchitis) was higher for SYMBICORT than placebo

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may occur, particularly at higher doses. Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids.

Patients who are receiving SYMBICORT should not use additional formoterol or other LABA for any reason.

Due to possible immunosuppression, potential worsening of infections could occur; a more serious course of chickenpox or measles can occur in susceptible patients.

Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. SYMBICORT, like all products containing sympathomimetic amines, should be used with caution in patients with convulsive disorders, thyrotoxicosis, and cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Beta-adrenergic agonist medications may produce hypokalemia and hyperglycemia in some patients. As with other inhaled medications, paradoxical bronchospasm may occur with SYMBICORT. Use with caution in patients with diabetes mellitus.

Long-term use of orally inhaled corticosteroids, such as budesonide, a component of SYMBICORT, may result in a reduction in growth velocity and/or a loss of bone mineral density.

Glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids, including budesonide, a component of SYMBICORT.

In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions.

SYMBICORT should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents. Caution should also be exercised in patients on long-term ketoconazole and other known potent CYP3A4 inhibitors. Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.

The most common adverse events ≥ 3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection.

WARNING: Long-acting beta2-adrenergic agonists (LABA), such as formoterol, one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. A placebo-controlled study with another LABA (salmeterol) showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including formoterol. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients.

Indications

SYMBICORT 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

SYMBICORT is NOT indicated for the relief of acute bronchospasm and should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD

Please see full Prescribing InformationAdobe PDF documentOpens in a new window, including boxed WARNING.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call
1-800-FDA-1088.

For PatientLog In

Log In

Close
* = Required field
Forgot Password?

Not Registered?

Sign Up Today

For PatientLog In

Forgot Your Password?

Close
* = Required field
Return to Log In

For PatientLog In

Log In

Close
Try logging in again

For PatientLog In

Thank you

Close

You should receive a temporary password shortly. It has been sent to the e-mail address associated with this account. Please check your e-mail and return to log in.

Return to Log In

AZ Gateway For Patient
Close

AZ TouchPoints News

The AZ TouchPoints Web site gives you direct access to AstraZeneca services and support. Here, you can easily find online sample ordering, formulary information, and patient education materials for select AstraZeneca medicines.

Go to About AZ TouchPoints

AstraZeneca Professional Sites

To learn more about AstraZeneca medicines, visit the AZ corporate site for a complete list of professional Web sites.

Go to Web site directory

AstraZeneca Medical Affairs

Visit the AstraZeneca Medical Affairs Web site to get answers to questions about AZ products and medicines.

Go to AZ US Medical Information

Close

If you would like information regarding products from AstraZeneca, please call

1-866-480-0036

Monday through Friday, 8:00 am to 6:00 pm ET, excluding holidays.

Close

Find My Representative

* = Required field
Find your Personal Account Specialist for NEXIUM®, who can answer questions and provide information about esomeprazole magnesium. Fill out the fields below to get started.
Review full Prescribing information for NEXIUM

 


OR

Call Me Now

Find your Personal Account Specialist for NEXIUM®, who can answer questions and provide information about esomeprazole magnesium. Fill out the fields below to get started.

* = Required field

- - -